PHGDH and hepatocellular carcinoma: PHGDH has been implicated as a driver of sorafenib resistance in HCC, and treatment with the PHGDH inhibitor NCT-503 has been shown to synergize with sorafenib, effectively inhibiting HCC growth in vivo71.